2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS 178306-51-9 Purity ≥99.0% (HPLC) Factory

Short Description:

Name: 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid

CAS: 178306-51-9

Appearance: White or Off-White Powder

Purity: ≥99.0% (HPLC)

Intermediate of (CAS: 177036-94-1) in the treatment of Pulmonary Arterial Hypertension (PAH)

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid
CAS Number 178306-51-9
CAT Number RF-PI161
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C16H16O4
Molecular Weight 272.3
Density 1.248
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Powder
Purity ≥99.0% (HPLC) 
Moisture (K.F) ≤1.00%
Single Impurity ≤0.50%
Total Impurities ≤1.00%
Test Standard Enterprise Standard
Usage Intermediate of API (CAS: 177036-94-1)

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid (CAS: 178306-51-9) with high quality,  it's a key intermediate of API (CAS: 177036-94-1). (CAS: 177036-94-1) is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. It is the third ET-receptor antagonist to be marketed for this indication behind bosentan and sitaxsentan. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. 

  • Write your message here and send it to us